CSIMarket Company Name, Ticker, Customers, else..
 
Vaxcyte Inc   (NASDAQ: PCVX)
Other Ticker:  
 
 
Price: $74.3700 $1.35 1.849%
Day's High: $75.04 Week Perf: 7.95 %
Day's Low: $ 72.89 30 Day Perf: -12.94 %
Volume (M): 835 52 Wk High: $ 121.06
Volume (M$): $ 62,106 52 Wk Avg: $84.56
Open: $73.91 52 Wk Low: $58.10



 Market Capitalization (Millions $) 9,080
 Shares Outstanding (Millions) 122
 Employees 206
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -464
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 22

Vaxcyte Inc
Vaxcyte Inc is a biotechnology company focused on developing innovative vaccines to prevent infectious diseases. The company utilizes its comprehensive understanding of bacterial pathogens and immunology to develop vaccines that address significant unmet medical needs. Vaxcyte aims to protect people of all ages, from infants to adults, against a range of infectious diseases. Their vaccines are designed to provide long-lasting protection, improve public health, and reduce the burden of infectious diseases globally. Vaxcyte is committed to advancing vaccine research and development to make a significant impact on global healthcare.


   Company Address: 825 Industrial Road San Carlos 94070 CA
   Company Phone Number: 837-0111   Stock Exchange / Ticker: NASDAQ PCVX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC        4.32% 
APGE        6.39% 
CMPX        3.8% 
IBRX   -1.37%    
MRNA   -3.73%    
NVAX   -2.32%    
• View Complete Report
   



Shares

Vaxcyte Raises $1.5 Billion in Public Offering to Advance Vaccine Innovation,

Published Fri, Sep 6 2024 8:05 PM UTC

Vaxcyte Raises $1.5 Billion in Public Offering to Advance Vaccine Innovation
Vaxcyte, a clinical-stage vaccine innovation company, has announced the closing of a $1.5 billion public offering, including the full exercise of underwriters option to purchase additional shares. This successful fundraising effort will support the company s mission of engineering high-fidelity...
Financing Agreement

Vaxcyte Announces Pricing of $1.3 Billion Public Offering, Setting Stage for Accelerated Innovation and Financial Growth.,

Published Thu, Sep 5 2024 3:59 AM UTC


Introduction
Vaxcyte, Inc., a leading clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases, has recently declared the pricing of an underwritten public offering of common stock and pre-funded warrants. The offering, totaling approximately $1.3 billion, highlights Vaxcytens commitment to expanding its res...
Shares

Vaxcyte, Inc. Launches $1.0 Billion Offering to Drive Vaccine Innovation and Benefit Shareholders,

Published Tue, Sep 3 2024 8:02 PM UTC

Vaxcyte, Inc. Commences $1.0 Billion Common Stock and Pre-Funded Warrants Offering
SAN CARLOS, Calif., Sept. 03, 2024 - Vaxcyte, Inc. (Nasdaq: PCVX), a leading clinical-stage vaccine innovation company, announced today the commencement of an underwritten public offering of $1.0 billion worth of its common stock and pre-funded warrants. This strategic move reflects Vaxcyt...
Clinical Study

Vaxcyte?s 31-Valent Pneumococcal Vaccine VAX-31 Shows Strong Immune Response in Phase 1/2 Study for Older Adults,...

Published Tue, Sep 3 2024 11:08 AM UTC

In a significant advancement for public health, Vaxcyte has announced encouraging topline data from its Phase 1/2 clinical study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate designed for adults aged 50 and older. The data reveal that VAX-31 elicits strong opsonophagocytic activity (OPA) immune responses across all 31 serotypes tested, showcasing its potent...
Clinical Study

Unveiling VAX-31 A New Era of Pneumococcal Immunization in Older Adults

Published Mon, Sep 2 2024 10:41 PM UTC

Abstract In an era where vaccine development is more vital than ever, Vaxcyte, Inc., a leader in clinical-stage vaccine innovation, is poised to redefine the landscape of pneumococcal disease prevention with its 31-valent pneumococcal conjugate vaccine (PCV), VAX-31. Targeting an at-risk demographic adults aged 50 and older this vaccine candidate has been developed to com...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com